サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1592590

欧州のてんかん市場：2030年までの予測 - 地域別分析 - タイプ別、投与経路別、治療タイプ別、年齢層別、流通チャネル別

Europe Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel

出版日
ページ情報
英文 150 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
欧州のてんかん市場：2030年までの予測 - 地域別分析 - タイプ別、投与経路別、治療タイプ別、年齢層別、流通チャネル別
出版日: 2024年09月16日
発行: The Insight Partners
ページ情報: 英文 150 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

欧州のてんかん市場は、2022年に19億4,058万米ドルとなり、2030年までには26億2,605万米ドルに達すると予測され、2022年から2030年までのCAGRは3.9%と推定されます。

てんかん治療開発への投資増加が欧州のてんかん市場を牽引

ヘルスケア分野は、急速な技術開発とイノベーションによって変貌を遂げ、医療サービスとケアの質を向上させています。てんかん市場は、さまざまな成長戦略を実施する大小さまざまな企業や組織の存在によって特徴付けられています。資金調達が可能なため、企業や組織は生産レベルの向上、新市場への進出、新技術・改良技術への投資、研究開発への資源配分を行うことができます。てんかん市場における注目すべき投資のうち、市場の進展に寄与したものを以下にいくつか紹介します。

2023年3月、スウェーデン政府は、スウェーデンのイノベーション機関であるVinnovaに総額770万米ドル（8,000万クローネ）を委託し、細胞治療や遺伝子治療などの先端治療の商業化、技能開発、生産能力増強のための国家イノベーションクラスターを設立することを決定しました。

2022年11月、小児てんかんの発症を予防する新薬治療法を開発するプロジェクトに取り組んでいる英国アストン大学の治療者は、脳内の疾患メカニズムとてんかん予防法を発見するため、240万米ドル（200万ポンド）を授与されました。医学研究評議会から資金提供を受けたこの3年間のプロジェクトは、アストン大学健康・生命科学部の研究者が中心となり、ブリストル大学とJazz Pharmaceuticalsとの共同研究です。

2022年7月、Cerebral Therapeuticsは、埋め込み型注入てんかん治療薬を第3相開発に向けて準備するため、シリーズCラウンドで4,000万米ドルの資金を確保しました。この資金調達ラウンドは、RA Capital ManagementやPerceptive Advisorsなどの投資家に加え、Lynx1 Capital Managementが主導しました。Cerebral Therapeuticsは、経口製剤試験の被験者に見られた体重増加を引き起こすことなく、指定されたレベルのバルプロ酸塩を中枢神経系に投与することを意図しています。

2021年11月、インディアナ州の新興企業Neuravaは、Elevate Venturesが主導し、Purdue Foundry、UCB Biopharma、First Leaf Capital、iO Life Ventures、エンジェル投資家が参加するシード資金として65万米ドル以上を獲得しました。同社は、てんかんによる予期せぬ突然死のリスクが近づいていることをモニターし、ユーザーに警告するウェアラブルデバイスの開発に取り組んでいます。

2021年6月、バイオセラピューティクス企業であるNeurona Therapeutics Inc.は、慢性焦点性てんかん治療用の抑制性神経細胞治療薬NRTX-1001（臨床第1/2a相試験）を含む、様々な適応症を対象とした完全自社開発の既製細胞治療のパイプラインを推進するため、4,150万米ドルの資金調達に成功しました。

そのため、先進治療開発への投資が増加しており、てんかん市場の成長を後押ししています。

欧州のてんかん市場概要

欧州のてんかん市場は、ドイツ、英国、フランス、イタリア、スペイン、その他欧州に区分されます。同地域はてんかん市場で大きなシェアを占めています。欧州のてんかん市場は、高齢者人口の大幅な増加、規制当局による新薬の承認、同地域の発作に対する効果的な薬剤や治療法の改善・開発のための政府による資金提供の増加などの要因により、予測期間中に大きな成長が見込まれています。

欧州のてんかん市場の収益と2030年までの予測（百万米ドル）

欧州のてんかん市場のセグメンテーション

欧州のてんかん市場は、タイプ、投与経路、治療タイプ、年齢層、流通チャネル、国に分類されます。

タイプ別では、欧州のてんかん市場は進行性ミオクロニーてんかん、反射性てんかん、全般てんかん、その他に分類されます。2022年の市場シェアは全般てんかんが最大でした。

投与経路では、欧州のてんかん市場は経口、非経口、その他に分類されます。2022年には経口セグメントが最大の市場シェアを占めました。

治療タイプ別では、欧州のてんかん市場は第一世代医薬品、第二世代医薬品、第三世代医薬品に分類されます。2022年には、第3世代医薬品セグメントが最大の市場シェアを占めました。

年齢層別では、欧州のてんかん市場は大人と子供に二分されます。2022年の市場シェアは、大人セグメントが大きいです。

流通チャネルでは、欧州のてんかん市場は病院薬局、小売薬局、その他に分類されます。病院薬局セグメントが2022年に最も大きな市場シェアを占めました。

国別では、欧州のてんかん市場は英国、ドイツ、フランス、イタリア、スペイン、その他欧州に区分されます。2022年の欧州のてんかん市場シェアは英国が独占しました。

Abbott Laboratories、Pfizer Inc、Eisai Co Ltd、UCB SA、CombiGene AB、LivaNova Plc、Novartis AG、Medtronic Plc、GSK Plc、H. Lundbeck ASは、欧州のてんかん市場で事業を展開する主要企業の一部です。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察
  • 市場の魅力

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 欧州におけるてんかん治療薬のパイプラインスタディ

  • てんかん治療アプローチのパイプライン研究
    • 細胞・遺伝子治療アプローチ
    • カプセル化細胞バイオデリバリー（ECB）システム
    • てんかんの遺伝子治療臨床概要
      • てんかんの臨床研究に採用されている遺伝子療法
      • てんかんに対するウイルスベクターのパイプライン研究
      • てんかんに対する非ウイルス性ベクターのパイプライン研究
      • アデノ随伴ウイルス（AAV）を介した神経調節ペプチド - 概要
      • 遺伝子治療のための神経栄養因子
      • ヒトてんかん表現型に対するカリウムチャネル
      • 酵素誘導性抗てんかん薬

第5章 欧州のてんかん市場：主要市場力学

  • 市場促進要因
    • てんかん有病率の上昇
    • てんかん治療薬開発への投資の増加
  • 市場抑制要因
    • 製品の回収
  • 市場機会
    • 団体による啓発プログラムの急増
  • 今後の動向
    • 有望な治療アプローチとしての遺伝子治療
  • 促進要因と抑制要因の影響

第6章 てんかん市場：欧州の分析

  • 欧州のてんかん市場

第7章 欧州のてんかん市場分析：タイプ別

  • 進行性ミオクロニーてんかん
  • 反射性てんかん
  • 全般てんかん
  • その他

第8章 欧州のてんかん市場分析：投与経路別

  • 経口
  • 非経口
  • その他

第9章 欧州のてんかん市場分析：治療タイプ別

  • 第一世代医薬品
  • 第二世代医薬品
  • 第三世代医薬品

第10章 欧州のてんかん市場の分析：年齢層別

  • 大人
  • 子供

第11章 欧州のてんかん市場分析：流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第12章 欧州のてんかん市場：国別分析

  • 欧州
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州

第13章 業界情勢

  • てんかん市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第14章 企業プロファイル

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • CombiGene AB
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第15章 付録

図表

List Of Tables

  • Table 1. Europe Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
  • Table 11. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 13. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 14. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 15. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 19. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 20. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 21. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 23. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 24. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 25. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 26. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 28. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 29. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 33. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 34. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 35. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 36. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 37. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 38. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 39. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 40. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 41. Recent Organic Growth Strategies in Epilepsy Market
  • Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. Europe Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Europe: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Europe: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. United Kingdom: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Germany: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. France: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Spain: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. Italy: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in Epilepsy Market
目次
Product Code: BMIRE00030744

The Europe epilepsy market was valued at US$ 1,940.58 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to register a CAGR of 3.9% from 2022 to 2030.

Increasing Investments in Development of Epilepsy Therapies Drive Europe Epilepsy Market

The healthcare sector is transforming with rapid technological developments and innovation, enhancing healthcare services and quality of care. The epilepsy market is characterized by the presence of several small and large companies and organizations implementing various growth strategies. The availability of funding enables companies and organizations to boost production levels, expand into new markets, invest in new/improved technologies, and allocate more resources to R&D. A few of the notable investments in the epilepsy market, contributing to the market progress, have been mentioned below.

In March 2023, the Swedish government decided to commission Vinnova, Sweden's innovation agency, a total of US$ 7.7 million (80 million SEK) to establish a national innovation cluster for commercialization, skills development, and production capacity build-up for cell therapies and other advanced treatments such as gene therapy.

In November 2022, Scientists at Aston University in the UK, working on a project to develop new drug treatments to prevent the beginning of childhood epilepsy, were awarded US$ 2.4 million (£2 million) to discover the disease mechanism in the brain and the ways of epilepsy prevention. This three-year project funded by the Medical Research Council is a collaboration led by researchers in the College of Health and Life Sciences at Aston University, combined with Bristol University and Jazz Pharmaceuticals.

In July 2022, Cerebral Therapeutics secured US$ 40 million in the Series C round funding to get its implanted infusion epilepsy treatment ready for phase 3 development. The funding round was led by Lynx1 Capital Management among other investors, including RA Capital Management and Perceptive Advisors. Cerebral Therapeutics intends to deliver the specified levels of valproate to the central nervous system without causing weight gain, which was witnessed in subjects of oral formulation studies.

In November 2021, Neurava, a startup located in Indiana, received over US$ 0.65 million in seed funding led by Elevate Ventures with participation from Purdue Foundry, UCB Biopharma, First Leaf Capital, iO Life Ventures, and angel investors. The company is working on the development of a wearable device to monitor and alert users about the approaching risk of sudden, unexpected death caused by epilepsy.

In June 2021, Neurona Therapeutics Inc., a biotherapeutics company, successfully completed a US$ 41.5 million financing to advance the company's pipeline of wholly owned, off-the-shelf cell therapies for various indications, including NRTX-1001 (a Phase 1/2a clinical study), an inhibitory neuronal cell therapy for the treatment of chronic focal epilepsy.

Therefore, increasing investments in the development of advanced treatments propels the growth of the epilepsy market.

Europe Epilepsy Market Overview

The European epilepsy market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy market. The European epilepsy market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Europe Epilepsy Market Segmentation

The Europe epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Europe epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Europe epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Europe epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Europe epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Europe epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Europe epilepsy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Europe epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Europe Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Europe Analysis

  • 6.1 Europe: Epilepsy Market

7. Europe Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Europe Epilepsy Market - Country Analysis

  • 12.1 Europe: Epilepsy Market Overview
    • 12.1.1 Europe: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
      • 12.1.1.1 United Kingdom: Epilepsy Market Overview
      • 12.1.1.2 United Kingdom: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 United Kingdom: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 United Kingdom: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 United Kingdom: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 United Kingdom: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 United Kingdom: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.3 Germany: Epilepsy Market Overview
      • 12.1.1.4 Germany: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.4.1 Germany: Epilepsy Market Breakdown, by Type
        • 12.1.1.4.2 Germany: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.4.3 Germany: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.4.4 Germany: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.4.5 Germany: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.5 France: Epilepsy Market Overview
      • 12.1.1.6 France: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.6.1 France: Epilepsy Market Breakdown, by Type
        • 12.1.1.6.2 France: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.6.3 France: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.6.4 France: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.6.5 France: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.7 Spain: Epilepsy Market Overview
      • 12.1.1.8 Spain: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.8.1 Spain: Epilepsy Market Breakdown, by Type
        • 12.1.1.8.2 Spain: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.8.3 Spain: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.8.4 Spain: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.8.5 Spain: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.9 Italy: Epilepsy Market Overview
      • 12.1.1.10 Italy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.10.1 Italy: Epilepsy Market Breakdown, by Type
        • 12.1.1.10.2 Italy: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.10.3 Italy: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.10.4 Italy: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.10.5 Italy: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.11 Rest of Europe: Epilepsy Market Overview
      • 12.1.1.12 Rest of Europe: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.12.1 Rest of Europe: Epilepsy Market Breakdown, by Type
        • 12.1.1.12.2 Rest of Europe: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.12.3 Rest of Europe: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.12.4 Rest of Europe: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.12.5 Rest of Europe: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 CombiGene AB
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 LivaNova Plc
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Novartis AG
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 Medtronic Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 GSK Plc
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments
  • 14.10 H. Lundbeck AS
    • 14.10.1 Key Facts
    • 14.10.2 Business Description
    • 14.10.3 Products and Services
    • 14.10.4 Financial Overview
    • 14.10.5 SWOT Analysis
    • 14.10.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners